US inspectors left Piramal's Whalton Road drug factory in Morpeth with a Form 483 listing seven observations. What that means, and what happens next.

Inspectors from the US Food and Drug Administration (FDA) spent nine days at Piramal Pharma’s drug factory on Whalton Road in Morpeth this month. They left the company with a list of seven observations.

The inspection ran from Thursday 3 September to Friday 11 September 2026. It checked the site against Good Manufacturing Practice (GMP), the rules for how medicines are made. At the end, the FDA issued a Form 483, the document inspectors hand over when they have seen something they think may breach US drug law.

Piramal Pharma, which is listed in Mumbai, disclosed this in a filing to the Bombay and National stock exchanges on Monday 14 September. The filing does not say what the seven observations are.

What Piramal says

The company’s filing describes the observations as “related to enhancement in our practices, procedures and documentation”. It says it is “diligently addressing these observations and is preparing a detailed response for submission to the US FDA within the stipulated timeline”.

It adds that it “will work closely with the agency to comprehensively address all the observations”. Nothing in the filing mentions a stop to production.

What a Form 483 is, and is not

A Form 483 is not a fine and it is not a verdict. The FDA’s own Form 483 FAQ says it “does not constitute a final Agency determination” that any law has been broken.

The FDA’s overview of drug manufacturing inspections sets out what happens next:

  • the company is strongly encouraged to reply within 15 business days with a corrective action plan
  • counted from the last day of the inspection, that is around Friday 2 October
  • the FDA then weighs the inspectors’ report, the evidence and the company’s reply
  • the FDA aims to tell a site its final inspection classification within 90 days of the inspection ending, which here would be by around 10 December

The same FDA document lists three classifications: no action indicated, voluntary action indicated and official action indicated. Which one Morpeth gets is not yet known.

Why the Morpeth site matters

The factory sits on the B6524 Whalton Road, on the south-west edge of Morpeth beside the A1. Piramal’s own page for the site describes it as “a USFDA and MHRA inspected, fully integrated site”. It develops and makes active pharmaceutical ingredients and oral solid medicines, for drug developers and generic manufacturers.

The same page says the site has more than 40 years’ experience of handling hormonal products.

A solar farm on the same site, announced two days later

The inspection news landed in the same week as a more positive announcement. On Wednesday 16 September Piramal Pharma Solutions announced a ground-mounted solar plant at the Morpeth site.

According to the company’s release, the plant will have:

  • a capacity of 4.3 megawatts peak
  • about 6,200 solar panels across 16 acres
  • output of about 3,950 MWh a year, around 22% of the site’s electricity
  • a start date in the first quarter of 2027

The power will be supplied under a purchase agreement with Alight UK BTM1 Limited, a solar developer. The company estimates the plant will avoid about 20,000 tonnes of CO2 equivalent over 25 years.

The scheme has been through Northumberland County Council’s planning system. The council’s register shows:

  • 23/03856/RENE, the solar array itself, received October 2023 and permitted on 25 June 2024
  • 26/00039/VARYCO, a change to the approved surface water drainage, permitted on 15 April 2026

Timeline of the FDA inspection and the solar plant at Piramal's Morpeth factory

What it means for you

  • If you work at the site: the company describes the observations as being about practices, procedures and documentation. Its filing says nothing about production stopping or jobs. The FDA’s decision on how to classify the inspection is the next milestone, due by around December.
  • If you take medicines made there: a Form 483 is not a recall, and the FDA says it is not a final finding. No recall has been announced in the filing.
  • If you live near Whalton Road: the solar plant already has planning permission, so there is no consultation to respond to. The company expects it to be running early next year.

We will update this page when Piramal submits its response or the FDA publishes its classification. Other planning decisions around the county are on our Northumberland planning news page.